Research Catalog

Devalued and distrusted : can the pharmaceutical industry restore its broken image?

Title

Devalued and distrusted : can the pharmaceutical industry restore its broken image? / John L. LaMattina, Ph. D.

Author

LaMattina, John L.

Publication

Hoboken, New Jersey : John Wiley & Sons, Inc., [2013]
©2013

Supplementary Content

Available Online

Table of contents

Items in the Library & Off-site

Filter by

1 Item

Item details
Status	Format	Access	Call Number	Item Location
Request for On-site Use Request Scan Available - Can be used on site. Please visit New York Public Library - Schwarzman Building to submit a request in person.	Text	Use in library	JBE 13-708	Schwarzman Building - General Research Room 315

Details

Description

ix, 125 pages : illustrations; 25 cm

Summary

"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--

Subjects

Bibliography (note)

Includes bibliographical references and index.

Contents

The four secrets the drug companies don't want you to know. Drug Companies Underestimate Dangerous Side Effects ; Drug Companies Control Much of the Information Your Doctor Gets ; You're Often Prescribed Drugs That You Don't Need ; Drugs Target the Symptoms, Not the Cause ; Conclusion ; References. -- What has happened to R & D productivity? Impact of Mergers on R & D Productivity ; Heightened FDA Requirements for NDAs ; Higher Hurdles Set by Payers ; Conclusion ; References. -- Key therapeutic areas for improving health. Cancer ; Diseases of the Brain ; Cardiovascular Disease (CVD) ; Diabetes ; Bacterial Infections ; Conclusion ; References. -- Improving R & D output. The Views of Others ; Pharma's Blockbuster Mentality Needs to Change ; Can "Predictive Innovation" Lead to Greater Success Rates? ; Would Royalties Make Scientists More Productive? ; Will Drug Repositioning Help Fill the R & D Pipeline? ; Consultants Don't Always Have the Facts ; Personal Views ; Discovery Must Focus on Productivity ; Does Size Help or Hinder R & D Productivity? ; To Outsource or Not to Outsource? That's the Pharma R & D Question ; Big Pharma Early Research Collaborations ; Conclusion ; References. -- Restoring Pharma's image. Illegal Detailing of Drugs ; Pharmaceutical Companies Should Drop TV Ads ; The Need for Greater Transparency ; How Committed Is Big Pharma to Rare Diseases? ; Pharmaceutical Companies and Philanthropy ; Pharma Needs to Have Its Scientists Tell Their Stories ; Conclusion ; References. -- Final thoughts. References.

Call Number